SAN DIEGO, Calif. — Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, announced that the U.S. Food and Drug Administration has cleared the Android version of the Tandem Mobi mobile app. The clearance expands access to the Tandem Mobi automated insulin delivery system for users who rely on Android smartphones.
Tandem Mobi is a compact, durable insulin pump powered by the company’s Control-IQ+ technology, which has been shown to support improvements in day-one use, maintain time spent in target glucose range, and increase overnight glucose stability.
“We’re excited to bring Tandem Mobi and the best-in-class outcomes of Control-IQ+ to Android users,” said John Sheridan, president and chief executive officer of Tandem Diabetes Care. “This latest integration gives Android users access to the life-changing benefits of Control-IQ+ on a system that emphasizes convenience, discretion, and customization.”
The Tandem Mobi mobile app is designed to pair securely with the insulin pump, enabling users to monitor and manage their therapy directly from a compatible smartphone. The app also connects to the Tandem Source platform, helping support communication between patients and healthcare providers for more informed decision-making and treatment adjustments.
“With the Tandem Mobi mobile app, we’re delivering a solution that meets patients where they are, on the devices they use every day, while maintaining the safety, reliability, and innovation they expect from Tandem,” said Dr. Jordan Pinsker, chief medical officer.
A limited release of the Android-compatible app is planned for December 2025, followed by broader commercial availability in early 2026. Once launched, the app will be available through the Google Play Store for select devices, including Google Pixel models 6 through 10 and Samsung Galaxy models S21 through S25. A full compatibility list will be issued closer to the commercial rollout.
